Trial Profile
A clinical study of Anti-SARS-CoV-2 hyperimmune globulin therapy
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 31 Jul 2020
Price :
$35
*
At a glance
- Drugs Anti-SARS-CoV-2 hyperimmune globulin therapy-Grifols (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Grifols
- 31 Jul 2020 New trial record
- 28 Jul 2020 According to a Grifols media release, the company announced that it has delivered the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials.
- 28 Jul 2020 According to a Grifols media release, this study is expected to begin this summer.